Aripiprazole Tablet
Product Images NDC 70518-2736

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2736). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole 2 mg oral tablets packaging label showing a quantity of 30 tablets. The label is from RemedyRepack Inc. and features manufacturing information for Ajanta Pharma USA Inc. It includes storage directions and a QR code.*

FDA Label Image

Figure4 (Aripiprazole Fig4)

A chart titled 'Aripiprazole Fold Change and 90% CI' depicting pharmacokinetic data comparing various special populations. The graph shows fold change and confidence intervals for Aripiprazole parameters (AUC, Cmax) across groups including CYP2D6 metabolism status, gender, age, hepatic impairment levels, and severe renal impairment, relative to reference values.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold changes in pharmacokinetic parameters (AUC and Cmax) relative to a reference. The chart compares the effects of CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment on dehydro-Aripiprazole levels, using horizontal lines with data points representing confidence intervals and relative change values on the x-axis.*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure diagram of Aripiprazole, showing its molecular formula with two chlorine atoms attached to a benzene ring linked to a piperazine ring and an indole derivative with a ketone group.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence intervals in Aripiprazole exposure with various interacting drugs. The y-axis lists drugs including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others like valproate, lithium, and lorazepam. The x-axis shows change relative to a reference with no interacting drug, from 0.5 to 3.0-fold.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A figure titled 'Effect of Other Drugs on Aripiprazole' showing dehydro-aripiprazole fold change and 90% confidence intervals for various interacting drugs. The chart plots change relative to a reference (without interacting drug) on the x-axis, with pharmacokinetic parameters AUC and Cmax for different drug categories including CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and others like valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A scatter plot illustrating the effect of Aripiprazole on various drugs by showing fold change and 90% confidence intervals. The x-axis represents the change relative to a reference without the interacting drug, and the y-axis lists different drugs and pharmacokinetic parameters such as AUC and Cmax. Data points indicate how Aripiprazole affects these parameters for each drug.*

FDA Label Image

Figure6 (Aripiprazole Fig 06)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over time for Aripiprazole versus Placebo. The x-axis indicates the number of days of randomization, and the y-axis shows the proportion with relapse. Subject counts at risk are displayed below the timeline for both groups.*

FDA Label Image

Aripiprazole_fig_07 (Aripiprazole Fig 07)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The chart includes a legend identifying Aripiprazole with a blue solid line and placebo with a red dashed line. The number of subjects at risk at various time points is listed below the x-axis for each group.*

FDA Label Image

Aripiprazole_fig_08 (Aripiprazole Fig 08)

A line chart comparing the proportion of subjects with relapse over days from randomization for Aripiprazole and placebo groups. The x-axis represents days from randomization, while the y-axis shows the proportion with relapse. The chart includes a legend and the number of subjects at risk at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.